Keywords
diagnostic procedures
mammography
ultrasonography
biopsy
Abstract
World wide, breast cancer is the most common malignancy in women. Despite an increased incidence of this cancer, the mortality rates have been maintained at the same level. This is due to the continuous development of therapeutic, as well as diagnostic methods because appropriate, effective treatment is dependent on accurate diagnosis. At the same time, the success is that more and more patients undergo breast- and axillary lymph nodes-sparing surgeries, therefore, determining the initial advancement stage of breast cancer is absolutely essential for ensuring proper therapy. This is a review of current guidelines for both early and advanced stages of breast cancer diagnostics. The principles described are largely based on the work of the European School of Oncology (ESO) and the European Society for Medical Oncology (ESMO). The review includes the rule of imaging studies, especially mammography screening and histopathological evaluation with molecular classification of breast cancer.References
1. Jagiełło-Gruszfeld A, Pogoda K, Kłak A, Stróżek J. Zalecenia dla polityki państwa w zakresie zaawansowanego raka piersi. Warszawa: Instytut Ochrony Zdrowia; 2017.
2. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;3:1194-220.
3. Helvie MA, Bevers TB. Screening mammography for average-risk women: The controversy and NCCN’s position. J Natl Compr Canc Netw. 2018;16:1398-404.
4. Gøtzsche PC. Mammography screening is harmful and should be abandoned. J R Soc Med. 2015;108:341-5.
5. Cancer Screening in the European Union 2017. Report on the implementation of the Council Recommendation on cancer screening. International Agency for Research on Cancer Lyon, France; 2017.
6. Patel BK, Lobbes MBI, Lewin J. Contrast enhanced spectral mammography: A review. Semin Ultrasound CT MR. 2018;39:70-9.
7. Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol. 2016;27:v103-v110. (Erratum in: Ann Oncol. 2017 Jul 1;28(suppl_4):iv167-iv168. PMID: 27664246)
8. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v8-30.
9. D’Orsi CJ, Getty DJ, Pickett RM, Sechopoulos I, Newell MS, Gundry KR, et al. Stereoscopic digital mammography: improved specificity and reduced rate of recall in a prospective clinical trial. Radiology. 2013;266:81-8.
10. Spak DA, Plaxco JS, Santiago L, Dryden MJ, Dogan BE. BI-RADS® fifth edition: A summary of changes. Diagn Interv Imaging. 2017;98:179-90.
11. Paydary K, Seraj SM, Zadeh MZ, Emamzadehfard S, Shamchi SP, Gholami S, et al. The evolving role of FDG-PET/CT in the diagnosis, staging, and treatment of breast cancer. Mol Imaging Biol. 2019;21:1-10.
12. Jassem J. Krzakowski M. Rak piersi. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Onkol Prakt Klin Edu. 2018;4:209-56.
13. Bick U, Trimboli RM, Athanasiou A, Balleyguier C, Baltzer PAT, Bernathova M, et al. European Society of Breast Imaging (EUSOBI), with language review by Europa Donna – The European Breast Cancer Coalition. Image-guided breast biopsy and localisation: recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights Imaging. 2020;11:12.
14. Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC cancer staging manual: Breast cancer. Ann Surg Oncol. 2018;25:1783-5.
15. Chen S, Liang Y, Feng Z, Wang M. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19:973.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2022 Authors